Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN
HCPLive
MAY 26, 2024
The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.
Let's personalize your content